WertQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMMittelzufluss aus Investitionstätigkeit8 000-2 000-3 000-7 0000-12 KZahlungsströme aus der Finanzierungstätigkeit1.35 M9.17 M40 K2.02 M12.4 M23.64 MFreier Cashflow-1.37 M-1.28 M-2.54 M-2.09 M-2.08 M-7.99 M
Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018.